MedTrace Logo

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

NCT04447651 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-07-14

No results posted yet for this study

Summary

This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.

Conditions

  • Metastatic Solid Tumor
  • SF3B1 Gene Mutation
  • Spliceosome Mutation
  • U2AF1 Gene Mutation
  • SRSF2 Gene Mutation

Interventions

OTHER

Recommendation for treatment with immunotherapy

Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.

Sponsors & Collaborators

  • Vanderbilt University

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Avon Breast Health Access Fund

    collaborator UNKNOWN

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Cesar Santa-Maria, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-17
Primary Completion
2023-05-15
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447651 on ClinicalTrials.gov